^
    Back
    Association details:
    Biomarker:EGFR wild-type
    Cancer:Lung Adenocarcinoma
    Drug:pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Tuberc Respir Dis (Seoul)
    Title:

    Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis

    Excerpt:
    Compared to conventional platinum-based chemotherapy, pemetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.
    DOI:
    https://doi.org/10.4046/trd.2017.0090